Physician profile
Debra Sowell
NPI 1760488118
$682.19
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $143 · 2022: $91.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $360.28 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $95.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.18 | 2020 | |
| Merck Sharp & Dohme LLC | $25.04 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $22.99 | 2022 | |
| Phadia US INC. | $16.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.71 | 2019 | |
| Corium, LLC | $15.34 | 2022 | |
| Pfizer INC. | $15.33 | 2022 | |
| Cranial Technologies, INC | $14.40 | 2019 | |
| Sanofi Pasteur INC. | $12.24 | 2022 | |
| Shire North American Group INC | $12.01 | 2019 | |
| Mission Pharmacal Company | $11.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Sowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.